07:00 , Jun 2, 2014 |  BC Week In Review  |  Clinical News

AVR560: Phase Ib started

AllaChem began a double-blind, placebo-controlled Phase Ib trial to evaluate once-daily 100 and 150 mg oral AVR560 for 14 days in treatment-naïve HCV patients. AllaChem LLC, Hallandale Beach, Fla.   Product: AVR560   Business: Infectious   Molecular...